FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Using AI in Drug Development

[ Price : $8.95]

Five Hogan Lovells attorneys discuss ways in which life sciences companies can use artificial intelligence in drug development and...

House Committee Advances FDA Funding Bill Amid Policy Disputes

[ Price : $8.95]

The U.S. House Appropriations Committee votes to approve a spending bill to fund FDA for fiscal year 2027.

1st Non-Antipsychotic OKd for Agitation in Alzheimers Patients

[ Price : $8.95]

FDA approves an expanded use for Axsome Therapeuticss Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) to trea...

FDA Panel Rejects Astrazenecas Camizestrant In Closely Watched Vote

[ Price : $8.95]

An FDA advisory committee votes 6 to 3 against supporting AstraZenecas investigational breast cancer therapy camizestrant.

Prospective AI Versioning Standard Needed: Post

[ Price : $8.95]

A Clinical Trial Vanguard online post makes the case for further FDA guidance so drug trial sponsors can successfully incorporate ...

Purdue Sentencing Sets $5.3 Billion in Criminal Penalties

[ Price : $8.95]

A federal court sentences Purdue Pharma to pay more than $5 billion in criminal penalties for its role in the U.S. opioid epidemic...

Reviewers Brief ODAC on Camizestrant Concerns

[ Price : $8.95]

FDA medical reviewers ask the Oncologic Drugs Advisory Committee to consider their concerns about the benefit-risk assessment of A...

Celgene Cell Therapy Facility Hit with Form 483

[ Price : $8.95]

FDA cites significant manufacturing and quality control concerns at a Celgene cell therapy facility in New Jersey, including defic...

GSK NDA Accepted for Hepatitis B Drug

[ Price : $8.95]

FDA accepts for priority review a GSK NDA for its investigational hepatitis B treatment bepirovirsen.

Insulet Class 1 Recall of Insulin Pump Components

[ Price : $8.95]

Insulet recalls (Class 1) certain insulin pump components, warning that continued use could result in severe injury or death.